{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:06:25Z","timestamp":1790845585679,"version":"4.1.0"},"reference-count":20,"publisher":"Hindawi Limited","issue":"6","license":[{"start":{"date-parts":[[2018,6,29]],"date-time":"2018-06-29T00:00:00Z","timestamp":1530230400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2018,6,29]],"date-time":"2018-06-29T00:00:00Z","timestamp":1530230400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Vertex Pharmaceuticals Inc, Boston, USA, through an Investigator Initiated Study (IIS) Grant."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pharm Ther"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1111\/jcpt.12722","type":"journal-article","created":{"date-parts":[[2018,6,30]],"date-time":"2018-06-30T05:31:19Z","timestamp":1530336679000},"page":"836-843","source":"Crossref","is-referenced-by-count":11,"title":["Does ivacaftor interfere with the antimicrobial activity of commonly used antibiotics against <i>Pseudomonas aeruginosa<\/i>\n?-Results of an in vitro study"],"prefix":"10.1155","volume":"43","author":[{"given":"B. C.","family":"Millar","sequence":"first","affiliation":[{"name":"Northern Ireland Public Health Laboratory; Department of Bacteriology; Belfast City Hospital; Belfast UK"},{"name":"School of Biomedical Sciences; Ulster University; Coleraine UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. C.","family":"Rendall","sequence":"additional","affiliation":[{"name":"Northern Ireland Regional Adult Cystic Fibrosis Centre, Level 8; Belfast City Hospital; Belfast UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. G.","family":"Downey","sequence":"additional","affiliation":[{"name":"Northern Ireland Regional Adult Cystic Fibrosis Centre, Level 8; Belfast City Hospital; Belfast UK"},{"name":"Centre for Experimental Medicine; Queen's University; Belfast UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. E.","family":"Moore","sequence":"additional","affiliation":[{"name":"Northern Ireland Public Health Laboratory; Department of Bacteriology; Belfast City Hospital; Belfast UK"},{"name":"School of Biomedical Sciences; Ulster University; Coleraine UK"},{"name":"Northern Ireland Regional Adult Cystic Fibrosis Centre, Level 8; Belfast City Hospital; Belfast UK"},{"name":"Centre for Experimental Medicine; Queen's University; Belfast UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"98","published-online":{"date-parts":[[2018,6,29]]},"reference":[{"key":"10.1111\/jcpt.12722-BIB0001|jcpt12722-cit-0001","doi-asserted-by":"crossref","first-page":"e45001","DOI":"10.1371\/journal.pone.0045001","article-title":"The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations","volume":"7","author":"Fodor","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1111\/jcpt.12722-BIB0002|jcpt12722-cit-0002","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1034\/j.1399-3003.2000.16d30.x","article-title":"Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus","volume":"16","author":"Doring","year":"2000","journal-title":"Eur Respir J"},{"key":"10.1111\/jcpt.12722-BIB0003|jcpt12722-cit-0003","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1741-7015-9-32","article-title":"Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis","volume":"9","author":"H\u00f8iby","year":"2011","journal-title":"BMC Med"},{"key":"10.1111\/jcpt.12722-BIB0004|jcpt12722-cit-0004","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1309\/KJRPC7DD5TR9NTDM","article-title":"Mucoid Pseudomonas in cystic fibrosis","volume":"128","author":"Pritt","year":"2007","journal-title":"Am J Clin Path"},{"key":"10.1111\/jcpt.12722-BIB0005|jcpt12722-cit-0005","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/09674845.2015.11666807","article-title":"Pseudomonas aeruginosa displays an altered phenotype in vitro when grown in the presence of mannitol","volume":"72","author":"Moore","year":"2015","journal-title":"Br J Biomed Sci"},{"key":"10.1111\/jcpt.12722-BIB0006|jcpt12722-cit-0006","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12722-BIB0007|jcpt12722-cit-0007","unstructured":"Anon Clinical and Laboratory Standards Institute 2005 Performance standards for antimicrobial susceptibility testing"},{"key":"10.1111\/jcpt.12722-BIB0008|jcpt12722-cit-0008","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/jcpt.12616","article-title":"Pseudomonas aeruginosa in cystic fibrosis patients with c.1652G\u203aA (G551D)-CFTR treated with ivacaftor-Changes in microbiological parameters","volume":"43","author":"Millar","year":"2018","journal-title":"J Clin Pharm Ther"},{"key":"10.1111\/jcpt.12722-BIB0009|jcpt12722-cit-0009","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jcf.2017.07.001","article-title":"Retrospective observational study of French patients with cystic fibrosis and a Gly551Asp-CFTR mutation after 1 and 2\u00a0years of treatment with ivacaftor in a real-world setting","volume":"17","author":"Hubert","year":"2018","journal-title":"J Cyst Fibros"},{"key":"10.1111\/jcpt.12722-BIB0010|jcpt12722-cit-0010","doi-asserted-by":"crossref","first-page":"L432","DOI":"10.1152\/ajplung.00461.2017","article-title":"Lumacaftor (VX-809) restores the ability of CF macrophages to phagocytose and kill Pseudomonas aeruginosa","volume":"314","author":"Barnaby","year":"2017","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1111\/jcpt.12722-BIB0011|jcpt12722-cit-0011","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.rmed.2017.08.026","article-title":"Ivacaftor for the p.Ser549Arg (S549R) gating mutation - The Israeli experience","volume":"131","author":"Dagan","year":"2017","journal-title":"Respir Med"},{"key":"10.1111\/jcpt.12722-BIB0012|jcpt12722-cit-0012","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.chest.2017.10.005","article-title":"CORK study in cystic fibrosis: sustained improvements in ultra-low-dose chest CT scores after CFTR modulation with ivacaftor","volume":"153","author":"Ronan","year":"2017","journal-title":"Chest"},{"key":"10.1111\/jcpt.12722-BIB0013|jcpt12722-cit-0013","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ijantimicag.2017.04.014","article-title":"Activity of innate antimicrobial peptides and ivacaftor against clinical cystic fibrosis respiratory pathogens","volume":"50","author":"Payne","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1111\/jcpt.12722-BIB0014|jcpt12722-cit-0014","doi-asserted-by":"crossref","first-page":"E37","DOI":"10.1002\/ppul.23665","article-title":"Pseudomonas eradication and clinical effectivness of Ivacaftor in four Hispanic patients with S549N","volume":"52","author":"Strang","year":"2017","journal-title":"Pediatr Pulmonol"},{"key":"10.1111\/jcpt.12722-BIB0015|jcpt12722-cit-0015","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1164\/rccm.201609-1954OC","article-title":"Restoring cystic fibrosis transmembrane conductance regulator function reduces airway bacteria and inflammation in people with cystic fibrosis and chronic lung infections","volume":"195","author":"Hisert","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1111\/jcpt.12722-BIB0016|jcpt12722-cit-0016","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1021\/acsinfecdis.6b00035","article-title":"An \u201cUnlikely\u201d pair: the antimicrobial synergy of polymyxin B in combination with the cystic fibrosis transmembrane conductance regulator drugs KALYDECO and ORKAMBI","volume":"2","author":"Schneider","year":"2016","journal-title":"ACS Infect Dis"},{"key":"10.1111\/jcpt.12722-BIB0017|jcpt12722-cit-0017","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/cid\/ciu944","article-title":"Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor","volume":"60","author":"Heltshe","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1111\/jcpt.12722-BIB0018|jcpt12722-cit-0018","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1164\/rccm.201404-0703OC","article-title":"Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis","volume":"190","author":"Rowe","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1111\/jcpt.12722-BIB0019|jcpt12722-cit-0019","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jcf.2014.02.004","article-title":"Antibacterial properties of the CFTR potentiator ivacaftor","volume":"13","author":"Reznikov","year":"2014","journal-title":"J Cyst Fibros"},{"key":"10.1111\/jcpt.12722-BIB0020|jcpt12722-cit-0020","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jchromb.2016.10.026","article-title":"Development of HPLC and LC-MS\/MS methods for the analysis of ivacaftor, its major metabolites and lumacaftor in plasma and sputum of cystic fibrosis patients treated with ORKAMBI or KALYDECO","volume":"1038","author":"Schneider","year":"2016","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12722","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jcpt.12722\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T18:03:47Z","timestamp":1671818627000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.12722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,29]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"URL":"https:\/\/doi.org\/10.1111\/jcpt.12722","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6,29]]}}}